Drug Approval | December 27, 2023
Eugia Pharma Specialities receives USFDA final approval for Posaconazole Injection
The product is expected to be launched in December 2023
The product is expected to be launched in December 2023
US FDA approval based on NEURO-TTRansform Phase III results
The LyondellBasell CirculenRenew polymers are made from renewable feedstocks derived from bio-based wastes
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
Development services for gene and cell therapies is planned to begin first in 2025
Subscribe To Our Newsletter & Stay Updated
